1. Measured by its binding ability in a functional ELISA. Immobilized human VEGF121b at 10μg/mL (100μL/well) can bind human VEGFR2-Fc, the EC50 of human VEGFR2-Fc is 0.06-0.1 μg/mL. 2. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 1-5ng/mL.

VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9.

Human

HEK293 Cells

MVCD1,VEGF,VPF,vascular endothelial growth factor A

Human VEGF 121 isoform b (P15692-9) (Met1-Asp147,with last 6 amino acids switch from CDKPRR to SLTRKD )

> 95 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy